Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: A randomized double-blind study

Mabuchi, Hiroshi; Nohara, Atsushi; Kobayashi, Junji; Kawashiri, Masa‐aki; Katsuda, Shoji; Inazu, Akihiro; Koizumi, Junji

doi:10.1016/j.atherosclerosis.2007.06.010

Cited by 91 publications

(81 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This findings is consistent with a study reporting no significant reduction in lipid profiles after 12 weeks supplementation with 100 mg/day CoQ10 in patient with non-alcoholic fatty liver disease (Mohammadshahi et al, 2014). Other study has also reported no significant change in serum lipids except a rise in HDL-C concentrations (Mabuchi et al, 2007).…”

Section: Discussionmentioning

confidence: 99%

Effects of coenzyme Q10 supplementation on the anthropometric variables, lipid profiles and liver enzymes in patients with non-alcoholic fatty liver disease

Jafarvand

Farhangi

Alipour

et al. 2015

Bangladesh J Pharmacol

View full text Add to dashboard Cite

<p class="Abstract">This randomized double-blind placebo-controlled trial was conducted on 41 patients with non-alcoholic fatty liver disease. Patients in intervention group received 100 mg/day coenzyme Q10 (CoQ10) for four weeks. There was a significant reduction in waist circumference and aspartate aminotransferase concentrations after CoQ10 supplementation (p<0.05). Dietary fiber was in negative correlation with change in serum alanine aminotransferase (ALT) concentrations (r = -410, p = 0.04), and dietary fat intake was in positive relation with serum triglyceride (r = 463, p = 0.04) and in negative relation with serum high-density lipoprotein cholesterol (HDL-C) (r = -533, p = 0.02) in CoQ10-treated group. CoQ10 supplement is able to reduce central obesity and improve liver function in non-alcoholic fatty liver disease. Dietary factors were also significant determinants of change in liver-specific enzyme ALT and lipid profile in these patients. Further trials with higher dose of CoQ10 and longer treatment periods are warranted to better clarify these findings.</p><p> </p>

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of coenzyme Q10 supplementation on the anthropometric variables, lipid profiles and liver enzymes in patients with non-alcoholic fatty liver disease

Jafarvand

Farhangi

Alipour

et al. 2015

Bangladesh J Pharmacol

View full text Add to dashboard Cite

show abstract

“…It has been shown that CoQ 10 supplementation (100 mg/d) in HC patients treated with atorvastatin (10 mg/d) did not have an effect on statin-induced reductions in total or LDL-cholesterol, or TAG levels (124) .…”

Section: Safety Aspects Of Combination Therapy With Coenzyme Q 10 Andmentioning

confidence: 98%

Support of drug therapy using functional foods and dietary supplements: focus on statin therapy

et al. 2010

View full text Add to dashboard Cite

Functional foods and dietary supplements might have a role in supporting drug therapy. These products may (1) have an additive effect to the effect that a drug has in reducing risk factors associated with certain conditions, (2) contribute to improve risk factors associated with the condition, other than the risk factor that the drug is dealing with, or (3) reduce drug-associated side effects, for example, by restoring depleted compounds or by reducing the necessary dose of the drug. Possible advantages compared with a multidrug therapy are lower drug costs, fewer side effects and increased adherence. In the present review we have focused on the support of statin therapy using functional foods or dietary supplements containing plant sterols and/or stanols, soluble dietary fibre, n-3 PUFA or coenzyme Q 10 . We conclude that there is substantial evidence that adding plant sterols and/or stanols to statin therapy further reduces total and LDL-cholesterol by roughly 6 and 10 %, respectively. Adding n-3 PUFA to statin therapy leads to a significant reduction in plasma TAG of at least 15 %. Data are insufficient and not conclusive to recommend the use of soluble fibre or coenzyme Q 10 in patients on statin therapy and more randomised controlled trials towards these combinations are warranted. Aside from the possible beneficial effects from functional foods or dietary supplements on drug therapy, it is important to examine possible (negative) effects from the combination in the long term, for example, in post-marketing surveillance studies. Moreover, it is important to monitor whether the functional foods and dietary supplements are taken in the recommended amounts to induce significant effects. Combination therapy: Dyslipidaemia: Statins: Functional foodsThe world market for functional foods (FF) and dietary supplements (DS) is expanding rapidly. In 2010 FF are expected to represent 5 % of the total global food market (1) and the market for DS is estimated at more than $60 billion worldwide (2) . In general, the target population of FF or DS is healthy individuals with slightly elevated risk factors or some physical discomfort. However, due to the fast growing market of FF or DS and the accompanying strong advertising and marketing, also patients on medication may be stimulated to use FF or DS. This may have several consequences for the quality of drug treatment as stated by de Jong et al. with the example of the combined intake of plant sterols and/or stanols and statins (3) . Whereas they addressed the additive effect of plant sterols and/or stanols on reducing LDL-cholesterol values in patients on statin treatment, their main focus was the possible negative aspects of the combination, such as unfavourable effects on patient adherence with drug treatment and increasing the potential for food-drug interactions.In the present review we will focus on the possible beneficial effects that FF or DS may have on drug therapy. Because of the large number of subjects treated suboptimally with statins (hydroxymethylglutaryl Co...

show abstract

“…Attempts to treat or avoid statin-induced adverse events by Q10 supplementation have also been performed. In two small intervention studies, n = 44 [18] and n = 49 [17], patients on statin therapy were randomized to Q10 or placebo for 12 or 16 weeks, respectively. No correlation between Q10 supplementation and change in myalgia score [18] or creatine kinase (CK) values [17] were found in these two studies.…”

Section: Discussionmentioning

confidence: 99%

“…In two small intervention studies, n = 44 [18] and n = 49 [17], patients on statin therapy were randomized to Q10 or placebo for 12 or 16 weeks, respectively. No correlation between Q10 supplementation and change in myalgia score [18] or creatine kinase (CK) values [17] were found in these two studies. In a third study, 76 patients on statin therapy who had developed new onset myalgia were randomized to 120 mg Q10 daily or placebo for 3 months in combination with continued statin therapy [16].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Statin‐induced Myopathy and Ubiquinone Levels in Serum – Results from a Prospective, Observational Study

Skilving

Ačimovič

Rane

et al. 2015

Basic Clin Pharma Tox

View full text Add to dashboard Cite

It has been suggested that an impaired ubiquinone (Q10) synthesis may be responsible for muscular side effects caused by statins. The primary aim of this study was to investigate whether low Q10 levels in serum could be used as a marker to predict the risk of developing statin-induced myopathy. The secondary aim was to compare the change in Q10 levels during statin treatment and differences between men and women. Serum samples from a prospective, observational study in statin-treated patients who were thoroughly followed regarding muscular symptoms were used. In this cohort, 16 developed myopathy and 126 had no muscular symptoms related to statin treatment. Q10 levels were measured with a novel LC-MS method at baseline and after 2 months of statin treatment. Q10 levels showed no correlation with the risk of developing statin-induced myopathy. Individuals with low levels, Q10 < 200 ng/ml, at baseline had no increased risk of developing myopathy. In consistence with earlier reports, we showed that Q10 levels were reduced by 30% during statin treatment. There was no significant difference in the reduction between patients with or without myopathy. Women had approximately 30% lower Q10 levels compared to men both before and after treatment. In this study, there was no association between Q10 levels at baseline and statin-induced muscular side effects during a 2-month follow-up period, and our results indicate that Q10 levels in serum is not a useful marker to predict statin-induced myopathy.Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are used for treatment of hypercholesterolaemia and have a pronounced, preventive effect on serious cardiovascular events and mortality [1,2]. Today, statins are some of the most prescribed drugs in the Western world, and the consumption is steadily increasing [3]. However, several reports have demonstrated that statin-induced muscular side effects such as myalgia are more common than first demonstrated in clinical trials. In fact, 10-15% of patients prescribed statins may experience muscle symptoms [4][5][6]. The statin-induced myopathy is considered to be dose dependent [7] but independent of the cholesterol-lowering effect [8].Statins affect not only the synthesis of cholesterol but also all products in the cholesterol biosynthesis pathway.Ubiquinone (Q10) is one of these products. The major part of the intracellular Q10 is present in the inner mitochondrial membrane as an essential part of the electron transport chain [9,10]. A smaller fraction is present in the cytosol where it has antioxidative functions [9,11]. Q10 is also present in the blood and is mainly bound to low-density lipoprotein (LDL) and also, to some extent, to high density lipoprotein (HDL) and very low-density lipoprotein (VLDL) [12].It has been suggested that the decreased synthesis of Q10 may be involved in statin-induced myopathy [13,14]. In particular, the reduction of mitochondrial Q10 has been suggested to cause myopathy, and statin treatments have been shown to negatively a...

show abstract

Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: A randomized double-blind study

Cited by 91 publications

References 25 publications

Effects of coenzyme Q10 supplementation on the anthropometric variables, lipid profiles and liver enzymes in patients with non-alcoholic fatty liver disease

Effects of coenzyme Q10 supplementation on the anthropometric variables, lipid profiles and liver enzymes in patients with non-alcoholic fatty liver disease

Support of drug therapy using functional foods and dietary supplements: focus on statin therapy

Statin‐induced Myopathy and Ubiquinone Levels in Serum – Results from a Prospective, Observational Study

Contact Info

Product

Resources

About